Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00118924 · ClinicalTrials.gov registry record · Phase 1
Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults
A Phase 1 study of Tick-Borne Encephalitis, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT00118924 is a Phase 1 study of Tick-Borne Encephalitis that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 28 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00118924, a Phase 1 study of Tick-Borne Encephalitis, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
Tick-borne encephalitis (TBE) is a viral illness common in the Northern Hemisphere, especially Europe and Asia. TBE infection may lead to central nervous system problems and death. The purpose of this study is to test the safety of and immune response to a TBE vaccine in healthy adults. The vaccine is related to a live attenuated virus developed against dengue virus infection.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL LGT(TP21)/DEN4
Study Locations (1)
Tennessee
- Vanderbilt University School of Medicine - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2005-07 |
| Est. Completion | 2007-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00118924
The ClinicalTrials.gov registry entry for NCT00118924 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tick-Borne Encephalitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00118924 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT00118924 about?
NCT00118924 is a clinical study titled "Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults". Tick-borne encephalitis (TBE) is a viral illness common in the Northern Hemisphere, especially Europe and Asia. TBE infection may lead to central nervous system problems and death. The purpose of this study is to test the safety of and immune response to a TBE vaccine in healthy adults. The vaccine ...
What is the current status of trial NCT00118924?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2005-07. Estimated completion is 2007-07.
What conditions does trial NCT00118924 study?
This clinical trial studies the following conditions: Tick-Borne Encephalitis.
What interventions are being tested in trial NCT00118924?
The interventions under investigation include: Placebo (BIOLOGICAL), LGT(TP21)/DEN4 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00118924?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00118924 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.